• Liquid nitrogen- (LN2) based ProSense found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage
• Independent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense for indications that are approved in various markets across the world

CAESAREA, Israel, Sept. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study led by Dr. Franco Orsi, Director of Interventional Radiology at the European Institute of Oncology (IEO) in Milan, Italy and an expert ProSense user. The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.